TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17541653
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 60,000 U SC QW during initial dosing phase (IDP)
Study: 17541653
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 80,000 U SC Q3W during extended dosing phase (EDP)
Study: 17562873
Drug: Clofarabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (20 mg/m2) + cyclophosphamide (200 mg/m2)
Study: 17562873
Drug: Clofarabine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (10 mg/m2) + cyclophosphamide (200 mg/m2)
Study: 17562873
Drug: Cyclophosphamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (200 mg/m2) alone
Study: 17563348
Drug: Annual 4-day
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual 4-day insulin infusions and daily insulin injections
Study: 17563856
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg once daily and docetaxel 75 mg/m(2) every 3 weeks
Study: 17573882
Drug: Imiquimod treatment
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod treatment for AIN
Study: 17577020
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 400 mg daily until disease progression or intolerable toxicity
Study: 17577020
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 400 mg daily
Study: 17579195
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone deficiency (GHD)
Study: 17586030
Drug: HspE7 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HspE7 (500 microg, 3 monthly subcutaneous vaccinations)
Study: 17586305
Drug: Low-dose AAV-GAD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AAV-GAD gene therapy
Study: 17586305
Drug: Medium-dose AAV-GAD
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose AAV-GAD gene therapy
Study: 17586305
Drug: High-dose AAV-GAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AAV-GAD gene therapy
Study: 17586305
Drug: AAV-GAD gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV-GAD gene therapy
Study: 17586747
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with rosiglitazone and exercise
Study: 17591525
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU once weekly for 12 weeks and once monthly thereafter for a total of 6 months
Study: 17591525
Drug: Ergocalciferol administration
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol administration
Study: 17596541
Drug: 5-azacitidine (5-AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-azacitidine (5-AZA) at 75 mg/m² subcutaneously daily for 7 days, valproic acid (VPA) orally daily for 7 days (dose-escalated, maximum tolerated dose 50 mg/kg), all-trans retinoic acid (ATRA) at 45 mg/m² orally daily for 5 days starting on day 3.
Study: 17596541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-AZA, VPA, and ATRA
Study: 17597266
Drug: CJ-50300 smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJ-50300 smallpox vaccine
Study: 17626713
Drug: Atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10, 20, 40, 80 mg/day)
Study: 17635942
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg at 10- to 14-wk intervals
Study: 17646603
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors prescribed at discharge
Study: 17647221
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (n = 64) with educational materials, 90 minutes once a week for a minimum of 1 year.
Study: 17647221
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy for ER-negative participants.
Study: 17647221
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy for ER-positive participants.
Study: 17659962
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection (1.25 mg/0.05 ml)
Study: 17666616
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor regimen
Study: 17666616
Drug: No protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: No protease inhibitor regimen
Study: 17679729
Drug: Decitabine alone
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine alone (20 mg/m(2)/d intravenously for 10 days)
Study: 17679729
Drug: Decitabine plus
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine plus valproic acid (VA) (at OBD, days 1 through 10, with dose-escalating VA days 5 through 21)
Study: 17684047
Drug: Standard replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard replacement therapy for adrenal insufficiency
Study: 17686450
Drug: One-drug group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-drug group (prostaglandin analogs)
Study: 17686450
Drug: Two-drug group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug group (prostaglandin analogs plus adjunctive medication)
Study: 17686450
Drug: Beta-adrenoceptor antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor antagonists (part of two-drug group)
Study: 17687130
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²) administered as four weekly infusions
Study: 17694552
Drug: Darbepoetin-alpha at
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin-alpha at a dose of 200 microg every 2 weeks
Study: 17700015
Drug: CVVH without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVVH without regional citrate anticoagulation (anticoagulant-free predilution CVVH)
Study: 17707182
Drug: Discharge use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker
Study: 17709602
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg daily) dose de-escalation
Study: 17709602
Drug: Reinitiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinitiation of therapy at prior effective dose
Study: 17709602
Drug: Imatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (300 to 400 mg daily)
Study: 17709827
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (cycles 2-7)
Study: 17717136
Drug: Valproate (VPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (VPA), a histone deacetylase inhibitor, used as a chronic treatment for epileptic disorders.
Study: 17717285
Drug: Flexible intensive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible intensive insulin therapy
Study: 17723147
Drug: ORAL IMPACT
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ORAL IMPACT (immunonutrient formula)
Study: 17725843
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg once a day for 12 weeks)
Study: 17761590
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (previously received)
Study: 17761710
Drug: Hydralazine (182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (182 mg for rapid acetylators, 83 mg for slow acetylators) and magnesium valproate (40 mg/kg) added to chemotherapy schedule.
Study: 17761710
Drug: Chemotherapy (cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, anastrozole).
Study: 17767471
Drug: Lansoprazole treatment
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole treatment for 5 years (median)
Study: 17822557
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with HER2 ICD protein-containing dendritic cells (DC) administered intradermally/subcutaneously four times at 3 week intervals.
Study: 17846226
Drug: pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly) followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years
Study: 17869664
Drug: Estimated brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated brachytherapy dose to APA
Study: 17875804
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine of PR1 and WT1 peptides in Montanide adjuvant with granulocyte-macrophage colony-stimulating factor
Study: 17875804
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine of PR1 and WT1 peptides
Study: 17876370
Drug: Topical acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acetylcholine chloride
Study: 17893227
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral lenalidomide daily
Study: 17893227
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lenalidomide on days 1 to 21 of a 28-day cycle
Study: 17893227
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lenalidomide
Study: 17897470
Drug: Active nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nitric oxide releasing patches
Study: 21831297
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine patch
Study: 17910637
Drug: UCB graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB graft with CD34(+) cell dose
Study: 17910637
Drug: UCB graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB graft with CD3(+) cell dose
Study: 17910637
Drug: UCB graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB graft with higher cell doses of CD34(+), committed CD34(+) progenitors and CD3(+) T cells
Study: 17915028
Drug: Electronic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic prescribing software with decision support at the point of care; details on dosage and duration not applicable as it is a software intervention.
Study: 17915977
Drug: Lamotrigine (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (dosing ranged from 25 mg every other day to 300 mg/day)
Study: 17916243
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment with moxifloxacin followed by delayed elective cholecystectomy
Study: 17923600
Drug: Lower serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower serum sodium concentration (per 5-mEq/L increment)
Study: 17923600
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum urea nitrogen concentration (per 10-mg/dL increment)
Study: 17923600
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of lipid-lowering drug therapy
Study: 17934551
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.d. for 7 weeks
Study: 17934748
Drug: Low-dose mitomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mitomycin C (0.01 nM) for 2 weeks followed by 0.1 to 100 microM mitomycin C; P-glycoprotein expression analysis using flow cytometry, immunoblotting, and RT-PCR.
Study: 17934748
Drug: Low-dose mitomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mitomycin C (0.01 nM) with verapamil (4 microM); P-glycoprotein expression analysis.
Study: 17936715
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (vitrectomy, intravitreal triamcinolone acetonide injection, and macular laser photocoagulation)
Study: 17951527
Drug: Deferasirox at
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox at 20 mg/kg per day
Study: 17951527
Drug: Deferasirox at
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox at 30 mg/kg per day
Study: 17954810
Drug: homocysteine level
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: homocysteine level lowering therapy
Study: 17959855
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) at 0.15 mg/kg per day
Study: 17959855
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) at 0.2 mg/kg per day
Study: 17975162
Drug: Defucosylated anti-CCR4
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Defucosylated anti-CCR4 monoclonal antibody KM2760
Study: 17975162
Drug: Defucosylated anti-CCR4
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Defucosylated anti-CCR4 monoclonal antibody KM2760 combined with immunomodulatory cytokines (interleukin-12, IFN-alpha-2b, IFN-gamma)
Study: 17981652
Drug: Nelfinavir monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir monotherapy, 1250 mg orally, BID for 3 weeks
Study: 17984237
Drug: Octreotide-LAR 20
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide-LAR 20 mg/q28d
Study: 17984237
Drug: Octreotide-LAR 30
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide-LAR 30 mg/q28d
Study: 17984237
Drug: Octreotide-LAR 40
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide-LAR 40 mg/q28d
Study: 17989313
Drug: BiRD (Biaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiRD (Biaxin [clarithromycin] 500 mg orally twice daily, lenalidomide [Revlimid] 25 mg orally daily on days 1 to 21, dexamethasone 40 mg orally once weekly)
Study: 17996820
Drug: Beta-blockers at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers at hospital discharge
Study: 17996820
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers at hospital discharge
Study: 17999759
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly dosing of epoetin delta
Study: 17999759
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly dosing of epoetin delta
Study: 18003886
Drug: Ofatumumab 100
Normalized name: ofatumumab 100 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 100 mg (1 dose) + 500 mg (3 doses)
Study: 18003886
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg (1 dose) + 1000 mg (3 doses)
Study: 18003886
Drug: Ofatumumab 500
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 500 mg (1 dose) + 2000 mg (3 doses)
Study: 18005455
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 1.5 atm and 100% oxygen
Study: 18005455
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 1.3 atm and 24% oxygen
Study: 18021496
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 400-800 mg from day 4 to 84)
Study: 18024436
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening interpretation by 16 radiologists
Study: 18025537
Drug: Trandolapril therapy
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril therapy
Study: 18026714
Drug: Oral taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral taurine (TAU)
Study: 18026714
Drug: Intralipid and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid and heparin (IH) infusion
Study: 18042798
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus steroids
Study: 18042798
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus steroids (related donors)
Study: 18042798
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone (related donors)
Study: 18042798
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus steroids (unrelated donors)
Study: 18042798
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone (unrelated donors)
Study: 21098399
Drug: Nilotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (400 mg twice daily)
Study: 18053191
Drug: Bortezomib in
Normalized name: bortezomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib in combination with celecoxib (escalating doses of bortezomib on a weekly or twice-weekly schedule and celecoxib 200 mg to 400 mg twice daily)
Study: 18053199
Drug: Chlamydia screening
Normalized name: Chlamydia trachomatis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia screening and treatment for those found to be infected
Study: 18054887
Drug: Intravenous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bevacizumab (5 mg/kg)
Study: 18055730
Drug: Spinal analgesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal analgesia (7.5 mg bupivacaine)
Study: 18055865
Drug: Eculizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (600 mg every 7 +/- 2 days for 4 weeks; 900 mg 7 +/- 2 days later; followed by 900 mg every 14 +/- 2 days for a total treatment period of 52 weeks)
Study: 18056840
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of multilineage dysplasia (MLD) in 1332 individuals receiving intensive AML therapy
Study: 18070995
Drug: Placebo-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-based antihypertensive therapy
Study: 18071030
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a plus oral doxycycline (100 mg daily for 4 months)
Study: 18071034
Drug: Pergolide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide treatment (meta-analysis)
Study: 18078870
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (1.0 g/1000 kcal)
Study: 18079362
Drug: SGN-30 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-30 (4 dose levels: 2, 4, 8, or 12 mg/kg)
Study: 18079362
Drug: SGN-30 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-30 (6 weekly doses)
Study: 18082486
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel and acetylsalicylic acid
Study: 18084623
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus injection of ferumoxytol (carboxymethyl dextran-based magnetic nanoparticle)
Study: 18089335
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 to 100 mg/day) for invasive candidiasis (IC)
Study: 18089335
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 to 100 mg/day) for invasive aspergillosis (IA)